Navigation Links
Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting
Date:5/28/2009

erythropoietin antibody-mediated anemia is confirmed, PROCRIT should be permanently discontinued and patients should not be switched to other erythropoietic proteins.
  • The safety and efficacy of PROCRIT therapy have not been established in patients with a known history of a seizure disorder or underlying hematologic disease (e.g., sickle cell anemia, myelodysplastic syndromes, or hypercoagulable disorders).
  • In some female patients, menses have resumed following PROCRIT therapy; the possibility of pregnancy should be discussed and the need for contraception evaluated.
  • Prior to and regularly during PROCRIT therapy monitor iron status; transferrin saturation should be greater than or equal to 20% and ferritin should be greater than or equal to 100 ng/mL. During therapy absolute or functional iron deficiency may develop and all patients will eventually require supplemental iron to adequately support erythropoiesis stimulated by PROCRIT.
  • Treatment of patients with grossly elevated serum erythropoietin levels (e.g., >200 mUnits/mL) is not recommended.
  • During PROCRIT therapy, blood pressure should be monitored carefully and aggressively managed, particularly in patients with an underlying history of hypertension or cardiovascular disease.
  • In studies, the most common side effects included fever (pyrexia), diarrhea, nausea, vomiting, swelling of hands or feet (edema), lack or loss of strength or weakness (asthenia, fatigue), shortness of breath, high blood pressure, headache, joint pain (arthralgias), abnormal skin sensations (as tingling or tickling or itching or burning; paresthesia), rash, constipation and upper respiratory infection.

  • Please visit www.procrit.com for the full Prescribing Information, including the Boxed WARNINGS, and for the Medication Guide
    '/>"/>

    SOURCE Centocor Ortho Biotech Products, L.P.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11

    Related biology technology :

    1. Medarex Announces Extension of Broad Antibody Development Relationship with Centocor
    2. Centocor Announces Ustekinumab Biologic License Application Accepted for Filing by FDA
    3. Centocor/Janssen-Cilags Ustekinumab Will Become the Gold Standard for Psoriasis By 2011
    4. Centocor, Inc. and Schering-Plough Submit Application Requesting Approval of Golimumab in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
    5. Ortho Biotech, L.P. and Centocor, Inc. Alert Authorized Distributors and Prescribing Physicians About Stolen Product
    6. GeneNews provides Centocor access to its osteoarthritis program
    7. Baseline Research Indicates High Interest in Centocor-Ortho Biotechs SIMPONI(R)
    8. Ortho Biotech Supports FDA Advisory Committees Recommendations on Use of ESAs in Chronic Renal Failure Patients
    9. Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases
    10. New Orthopedic Surgical Robotics Company Opens Its Doors; Files with the FDA for Clearance of Its Flagship Product
    11. Innovative Neurotronics, a Subsidiary of Hanger Orthopedic Group, Earns the 2007 da Vinci Award for the WalkAide System
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/19/2014)... MA (PRWEB) December 18, 2014 iLab ... announced the appointment of Siri Bryant as the new ... new Director of Core Implementations. These two new leadership ... outstanding customer service by ensuring that iLab continues to ... “In the last four years, iLab has been deployed ...
    (Date:12/19/2014)... BURLINGTON, Mass. , Dec. 18, 2014  Decision ... dental biomaterial market will grow moderately through ... implant procedures and growing awareness of dental biomaterials all ... underdeveloped markets such as China ... incomes will bring dental procedures within reach for a ...
    (Date:12/17/2014)... (PRWEB) December 16, 2014 The ... since 2013, which is why IBISWorld updated its original ... continues to benefit from an intensified focus on environmental ... for new emission standards for power plants and a ... According to IBISWorld Industry Analyst Sarah Kahn, “a range ...
    (Date:12/17/2014)... N.J. (PRWEB) December 17, 2014 ... (Euronext: IPN; ADR: IPSEY), today announced ... (referred to as Somatuline®) was approved by the ... treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult ... advanced or metastatic disease to improve progression-free survival ...
    Breaking Biology Technology:iLab Solutions Announces Two New Leadership Positions to Meet the Needs of Its Growing Customer Base 2Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 2Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 3Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 2Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8
    ... Sail graduate Darren Lynn Bousman, acclaimed Director of the ... its Full Sail Live facility on Monday, November 17, ... Repo! The Genetic Opera. The screening was followed by ... the university, and also featured actor and co-writer Terrance ...
    ... biotech firm and Laborium Biopharma, a subsidiary of Validapro Biosciences Inc. ... protein bioprocess production and scale-up. , ... Laval, Quebec ... firm and Laborium Biopharma, a subsidiary of Validapro Biosciences Inc. have ...
    ... ... St. Andrews by-the-Sea, ... https://www.atlanticabioenergy.com/ , NOTE TO EDITORS: Photo, video ... /PRNewswire/ - The global forestry industry is rapidly changing and it is incumbent on all stakeholders ...
    Cached Biology Technology:Full Sail University Welcomed Back to Campus Graduate and Acclaimed Horror Director, Darren Lynn Bousman 2Full Sail University Welcomed Back to Campus Graduate and Acclaimed Horror Director, Darren Lynn Bousman 3Med Discovery and Laborium Biopharma Sign a Bioprocess Development Partnership Agreement 2Media Advisory - Atlantica BioEnergy Task Force Leaders' Roundtable 2
    (Date:12/17/2014)... , Dec. 16, 2014 Valencell, a ... its PerformTek biometric technology to industry leaders such as ... accurate, clinically validated, biometric wearable products. These products will ... in Las Vegas . ... is accurate, flexible and robust – with the clinical ...
    (Date:12/15/2014)... 2014 Research and Markets ( ... "Global Facial Recognition Market 2015-2019" report ... http://photos.prnewswire.com/prnh/20130307/600769 Facial recognition is a ... recognition system measures the overall facial feature of ... and the distance between eyes. Facial recognition is ...
    (Date:12/11/2014)...  That blood pressure plays a role in human health ... medical term for high blood pressure – was first described ... cuff that,s used in measuring blood pressure was invented in ... about hypertension, its triggers and its effects. In fact, recent ... the best ways to treat it. For example, ...
    Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4
    ... The sweetgum tree grows widely throughout the country and is ... "gumballs." Now, this spiny fruit may become an important source ... bird flu ?a drug that is currently in short supply ... of the sweetgum fruit contain significant amounts of shikimic acid, ...
    ... A pain–killing medication appears to halt the production of ... of breast cancer, a new study using tissue cultures ... experiments on breast cancer cells, scientists found that derivatives ... implicated in estrogen-dependent breast cancer. This form of breast ...
    ... to show that molecular variation in one gene may ... habitat. Research Professor Ilkka Hanski, University of Helsinki, and ... the population growth of the Glanville fritillary butterfly (Melitaea ... phosphoglucose isomerase (Pgi) enzyme. The result challenges previous views ...
    Cached Biology News:Sweetgum tree could help lessen shortage of bird flu drug 2Pain killer fights breast cancer by targeting key enzyme 2Pain killer fights breast cancer by targeting key enzyme 3New discovery: Molecular variation in one gene affects the growth of natural populations 2
    Immunogen: Synthetic peptide: N(171) H G F L S A D Q QL I K(183) Storage: -20 C, Avoid Freeze/Thaw Cycles...
    The pCDF Expression System 1 plus Competent Cells contains 10 µg of pET-45b(+) DNA. pET-45b carries an N-terminal His•Tag ® coding sequence that is cleavable with enterokinase as well...
    HIV-1 TAT (vN-21)...
    Request Info...
    Biology Products: